2151 Las Palmas Drive
230 articles with Biocept, Inc.
Published Case Study Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for ALK Rearrangements
Peer-reviewed article in Oncology & Hematology Review highlights capability of Target Selector™ to detect a key biomarker to qualify lung cancer patients for targeted therapy when tissue biopsy is inadequate
Company to also co-host roundtable discussion
Biocept, Inc. reports financial results for the three and 12 months ended December 31, 2017, and provides an update on its business progress.
Collaboration plans to establish Biocept as Thermo Fisher Center of Excellence for liquid biopsy and to pursue commercial opportunities in both pharmaceutical and clinical markets.
Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform
In Japan, Biocept's patent no. 6234817 is entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION, and in Europe, Biocept's patent no. 2995953 is entitled DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS.
Biocept Announces Closing of $14.8M Public Offering of 32,854,606 Shares of Common Stock and Warrants to Purchase 32,854,606 Shares of Common Stock
The warrants have a per share exercise price of $0.50, are exercisable immediately and will expire five years from the date of issuance.
Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer
The evidence-based guidelines were developed in collaboration by the CAP, the IASCL, the AMP and the ASIP.
Biocept Announces Pricing of $15M Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common Stock
The warrants will have a per share exercise price of $0.50, are exercisable immediately and will expire five years from the date of issuance.
Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers
Data from 3,000 samples analyzed using Biocept's liquid biopsy assays for EGFR, BRAF and KRAS mutations demonstrated single mutant copy detection on the QS5 platform with more than 99% sensitivity and more than 99% specificity.
Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources
This is the second issued patent for Biocept's Target Selector assays for molecular analysis using real-time PCR, Sanger sequencing and NGS.
Biocept Signs In-Network Provider Agreement With Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota
The agreement marks Biocept's third Blue Cross Blue Shield contract and enables patients diagnosed with cancer the ability to access the Company's proprietary testing services in-network under their Wellmark health plan.
No warrants to purchase shares of the Company's common stock will be issued to the investors in connection with the offering.
First U.S. Patent Issued for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform
The patent encompasses Biocept's proprietary "switch-blocker" technology, which enriches patient specimens for oncogene mutations of interest, resulting in ultra-high sensitivity and specificity for the detection of cancer-associated mutations.
Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy
The 100-patient study is designed to clinically validate Biocept's Target Selector PD-L1 assay for patients diagnosed with NSCLC.
Biocept reports financial results for the three and nine months ended September 30, 2017, and provides an update on its business progress.
Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017
The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time.
Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals
Biocept announces the launch of its molecular pathology partnership initiative, the aim of which is to incorporate community pathologists into the review of biomarkers found in liquid biopsy for patients diagnosed with cancer.
Biocept And Miraca Life Sciences Enter Into Marketing Agreement To Expand Target Selector Testing In The United States